Thus, by regulating the iron metabolism of CCRCC cells, Tempol may have a potential therapeutic value for cancers dependent on HIF2α for growth and survival, such as CCRCC tumors. Here, EPAS1 is linked to nonpapillary renal cell carcinoma.